18 research outputs found

    Hemoglobin levels over time.

    No full text
    <p>Mean hemoglobin by treatment group over time is shown. The mean reduction at the end of treatment for the pooled ribavirin-containing arms was approximately 2.5 g/dL. TID16W/TID28W/TID40W, faldaprevir 120 mg once daily, deleobuvir 600 mg three times daily, and ribavirin for 16, 28, and 40 weeks, respectively; BID28W, faldaprevir 120 mg once daily, deleobuvir 600 mg twice daily, and ribavirin for 28 weeks; TID28W-NR, faldaprevir 120 mg once daily and deleobuvir 600 mg three times daily without ribavirin for 28 weeks.</p

    Baseline demographics and disease characteristics.

    No full text
    <p><sup>a</sup>Fibrosis stage was determined by either METAVIR score or fibroscan result; if a METAVIR score was not available, then a fibroscan result was used (fibroscan <9.5 = ≤F2 and fibroscan ≥9.5 = ≥F3). TID16W/TID28W/TID40W, faldaprevir 120 mg once daily and deleobuvir 600 mg three times daily plus ribavirin for 16, 28, and 40 weeks, respectively; BID28W, faldaprevir 120 mg once daily and deleobuvir 600 mg twice daily plus ribavirin for 28 weeks; TID28W-NR, faldaprevir 120 mg once daily and deleobuvir 600 mg three times daily, without ribavirin, for 28 weeks.</p><p>Baseline demographics and disease characteristics.</p

    Inosine triphosphatase (<i>ITPA</i>) gene single-nucleotide polymorphisms by treatment arm.

    No full text
    <p>TID16W/TID28W/TID40W, faldaprevir 120 mg once daily and deleobuvir 600 mg three times daily plus ribavirin for 16, 28, and 40 weeks, respectively; BID28W, faldaprevir 120 mg once daily and deleobuvir 600 mg twice daily plus ribavirin for 28 weeks; TID28W-NR, faldaprevir 120 mg once daily and deleobuvir 600 mg three times daily, without ribavirin, for 28 weeks.</p><p>Inosine triphosphatase (<i>ITPA</i>) gene single-nucleotide polymorphisms by treatment arm.</p

    Factors associated with anemia in univariate and multivariate analyses, all treated patients.

    No full text
    <p>Ribavirin-containing arms are pooled and all patients have the rs1127354 CC genotype. Covariates included age (<60 years vs ≥60 years), gender, weight (<75 kg vs ≥75 kg), fibrosis stage (F0–F2 vs F3–F4), presence of cirrhosis (yes/no), body mass index (<25 kg/m<sup>2</sup> vs ≥25 kg/m<sup>2</sup>), rs6051702 genotype (ITPA-deficient (CC/CA) vs–non-deficient (AA)), baseline hemoglobin (<15 g/dL vs ≥15 g/dL), faldaprevir, deleobuvir, and ribavirin trough levels through week 12, and baseline ribavirin dose. ITPA, inosine triphosphatase.</p><p>Factors associated with anemia in univariate and multivariate analyses, all treated patients.</p
    corecore